Literature DB >> 27629767

The expression of miRNA-221 and miRNA-222 in gliomas patients and their prognosis.

Liang Xue1, Yi Wang2, Shuyuan Yue2, Jianning Zhang2.   

Abstract

The aim of this study is to explore the expression of microRNA (miRNA)-221 and miRNA-222 in human glioma cells and tissues. The expression of miRNA-221 and miRNA-222 in human glioma cell line U87, U251, A172, LN229 and surgery resected glioma tissues were measured. The survival rate of X-ray (2 Gy) irradiated glioma cells were calculated. 165 cases of glioma patients were recruited successfully; the expression of miRNA-221 and miRNA-222 in their resected tissues were measured. The expression of miRNA-221 and miRNA-222 in cancer tissues were obviously higher than control tissues (normal brain tissue) and control cell (gastric mucosal epithelial cell, GES) (p < 0.05). The highly malignant glioma tissues expressed significantly higher miRNA-221 and miRNA-222 than low malignant glioma tissues. Patients with highly expressed miRNA-221 and miRNA-222 have shorter survival time. Survival rate of glioma cells was significantly higher than GES cell after irradiation (p < 0.05); miRNA-221 in glioma cells. The expressions of miRNA-221 and miRNA-222 in irritated glioma cells were positively correlated with the survival rate of glioma cells (r = 0.629, 0.712, both p < 0.01). For the 165 glioma patients, the expressions of miRNA-221 and miRNA-222 increased with the increasing of pathological grades (χ 2 = 42.85, p < 0.01); and their survival time decreased when miRNA-221 expression elevated (χ 2 = 57.12, p < 0.01). MiRNA-221 and miRNA-222 express highly in human glioma cells and tissues. Expression of miRNA-221 and miRNA-222 are closely related to pathological grading and prognosis of glioma; they could be used as independent prognostic factor for glioma.

Entities:  

Keywords:  Glioma; Prognostic factor; Radiosensitivity; Survival; miRNA-221; miRNA-222

Mesh:

Substances:

Year:  2016        PMID: 27629767     DOI: 10.1007/s10072-016-2710-y

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  32 in total

1.  A prospective study of surgical patterns of care for high grade glioma in the current era of multimodality therapy.

Authors:  A K Nowak; J E Maujean; M Jackson; N Knuckey
Journal:  J Clin Neurosci       Date:  2010-12-24       Impact factor: 1.961

2.  The Clinical Implications of Transforming Growth Factor Beta in Pathological Grade and Prognosis of Glioma Patients: A Meta-Analysis.

Authors:  Xiangshan Yang; Shunzeng Lv; Xingtong Zhou; Yuting Liu; Daotang Li; Ranran Shi; Huihui Kang; Jing Zhang; Zhongfa Xu
Journal:  Mol Neurobiol       Date:  2014-08-23       Impact factor: 5.590

Review 3.  Targeting strategies on miRNA-21 and PDCD4 for glioblastoma.

Authors:  Gang Wang; Jun Jie Wang; Hong Ming Tang; Shing Shun Tony To
Journal:  Arch Biochem Biophys       Date:  2015-07-02       Impact factor: 4.013

4.  MicroRNA-10b induces glioma cell invasion by modulating MMP-14 and uPAR expression via HOXD10.

Authors:  Lihua Sun; Wei Yan; Yingyi Wang; Guan Sun; Hui Luo; Junxia Zhang; Xiefeng Wang; Yongping You; Zhengxiang Yang; Ning Liu
Journal:  Brain Res       Date:  2011-03-16       Impact factor: 3.252

5.  Prognostic but not predictive role of platelet-derived growth factor receptors in patients with recurrent glioblastoma.

Authors:  Janna Paulsson; Maja Bradic Lindh; Malin Jarvius; Marjut Puputti; Monica Nistér; Nina N Nupponen; Werner Paulus; Ola Söderberg; Gregor Dresemann; Andreas von Deimling; Heikki Joensuu; Arne Ostman; Martin Hasselblatt
Journal:  Int J Cancer       Date:  2011-04-15       Impact factor: 7.396

6.  Extensive modulation of a set of microRNAs in primary glioblastoma.

Authors:  S A Ciafrè; S Galardi; A Mangiola; M Ferracin; C-G Liu; G Sabatino; M Negrini; G Maira; C M Croce; M G Farace
Journal:  Biochem Biophys Res Commun       Date:  2005-09-09       Impact factor: 3.575

Review 7.  Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: a systematic review.

Authors:  Li-Juan Yang; Chang-Fu Zhou; Zhi-Xiong Lin
Journal:  Cancer Invest       Date:  2013-12-14       Impact factor: 2.176

8.  Survival outcome of early versus delayed bevacizumab treatment in patients with recurrent glioblastoma.

Authors:  Mohamed A Hamza; Jacob J Mandel; Charles A Conrad; Mark R Gilbert; W K Alfred Yung; Vinay K Puduvalli; John F DeGroot
Journal:  J Neurooncol       Date:  2014-05-07       Impact factor: 4.130

9.  Lin28-let7 modulates radiosensitivity of human cancer cells with activation of K-Ras.

Authors:  Jee-Sun Oh; Jae-Jin Kim; Ju-Yeon Byun; In-Ah Kim
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-01-01       Impact factor: 7.038

10.  Low expression of insulin-like growth factor binding protein 7 associated with poor prognosis in human glioma.

Authors:  Xiangyang Tian; Ling Zhang; Laiguang Sun; Yihong Xue; Shuang Xie
Journal:  J Int Med Res       Date:  2014-04-17       Impact factor: 1.671

View more
  17 in total

1.  News on the journal Neurological Sciences in 2017.

Authors:  Ilaria Di Donato; Antonio Federico
Journal:  Neurol Sci       Date:  2018-01       Impact factor: 3.307

2.  Plasma miR-122 as a potential diagnostic and prognostic indicator in human glioma.

Authors:  Ying Tang; Shunfeng Zhao; Jiliang Wang; Dongfeng Li; Qingbo Ren; Yurong Tang
Journal:  Neurol Sci       Date:  2017-04-03       Impact factor: 3.307

3.  Sevoflurane Regulates Glioma Progression by Circ_0002755/miR-628-5p/MAGT1 Axis.

Authors:  Haoyi Li; Tian Xia; Yilin Guan; Yao Yu
Journal:  Cancer Manag Res       Date:  2020-06-30       Impact factor: 3.989

4.  MiR-1297 negatively regulates metabolic reprogramming in glioblastoma via repressing KPNA2.

Authors:  Huibing Li; Honggang Yuan
Journal:  Hum Cell       Date:  2020-03-02       Impact factor: 4.174

5.  Biomarker significance of plasma and tumor miR-21, miR-221, and miR-106a in osteosarcoma.

Authors:  Manjula Nakka; Wendy Allen-Rhoades; Yiting Li; Aaron J Kelly; Jianhe Shen; Aaron M Taylor; Donald A Barkauskas; Jason T Yustein; Irene L Andrulis; Jay S Wunder; Richard Gorlick; Paul S Meltzer; Ching C Lau; Tsz-Kwong Man
Journal:  Oncotarget       Date:  2017-05-27

6.  Identification of microRNAs associated with the survival of patients with gallbladder carcinoma.

Authors:  Jianguo Wang; Yuxia Jin; Suping Li; Qinhao Song; Ping Tang
Journal:  J Int Med Res       Date:  2020-05       Impact factor: 1.671

7.  Prognostic Significance of MicroRNAs in Glioma: A Systematic Review and Meta-Analysis.

Authors:  Yanming Zhang; Jigang Chen; Qiang Xue; Junyu Wang; Liang Zhao; Kaiwei Han; Danfeng Zhang; Lijun Hou
Journal:  Biomed Res Int       Date:  2019-03-26       Impact factor: 3.411

8.  Comparison of different protocols of RNA preparation from circulating blood for RNA sequencing.

Authors:  Shenghua Li; Lan Chen; Jinpin Li; Jingli Liu
Journal:  Biotechnol Lett       Date:  2021-06-25       Impact factor: 2.461

9.  Altered Expression of miR-575 in Glioma is Related to Tumor Cell Proliferation, Migration, and Invasion.

Authors:  Guangxin Wei; Shengjun Li; Pengcheng Wang; Shouxian Wang; Yujing Zhao
Journal:  Neuromolecular Med       Date:  2021-07-16       Impact factor: 3.843

10.  Circular RNA SMO sponges miR-338-3p to promote the growth of glioma by enhancing the expression of SMO.

Authors:  Zhiyong Xiong; Chaoyang Zhou; Luyang Wang; Ronglan Zhu; Liangchen Zhong; Dengfeng Wan; Qiangping Wang
Journal:  Aging (Albany NY)       Date:  2019-12-30       Impact factor: 5.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.